Clinical Trials Logo

Recurrent Uterine Corpus Cancer clinical trials

View clinical trials related to Recurrent Uterine Corpus Cancer.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02728258 Completed - Clinical trials for Endometrial Serous Adenocarcinoma

Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Start date: September 16, 2016
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well copanlisib works in treating patients with endometrial cancer that has not decreased or disappeared, and the cancer may still be in the body despite treatment (persistent) or has come back (recurrent). Copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01935973 Completed - Clinical trials for Endometrial Adenocarcinoma

Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer

Start date: September 30, 2013
Phase: Phase 1
Study type: Interventional

This randomized phase I trial studies how well trametinib with or without GSK 2141795 (protein kinase B [Akt] inhibitor GSK2141795) works in treating patients with endometrial cancer that has come back (recurrent) or does not go to remission despite treatment (persistent). Trametinib and Akt inhibitor GSK2141795 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether trametinib is a more effective treatment for endometrial cancer when given with or without ATK inhibitor GSK2141795.